The Proceedings of the 20th International Conference on Chelation held in the USA: Advances on new and old chelation therapies

Toxicology Mechanisms and Methods

Volumn 23, Issue 1, 2013, Pages 1-4

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Deferasirox; Deferiprone; Deferoxamine; EDTA; Iron overload; Metal imbalance and toxicity

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EDETIC ACID; HEAVY METAL; RADIOACTIVE MATERIAL;

ANTIOXIDANT ACTIVITY; CHELATION; CHELATION THERAPY; CLINICAL PROTOCOL; CONFERENCE PAPER; DETOXIFICATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEART INFARCTION; HEAVY METAL POISONING; HUMAN; IRON CHELATION; IRON OVERLOAD; MEDICAL SOCIETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; THALASSEMIA; UNITED STATES;

CHELATING AGENTS; CHELATION THERAPY; DEFEROXAMINE; EDETIC ACID; HUMANS; IRON OVERLOAD; METALS; POISONING; PYRIDONES; RISK ASSESSMENT; THALASSEMIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84871429166     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.720305     Document Type: Conference Paper

References (28)

1. Abergel RJ, Raymond KN. 2011. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Hemoglobin 35:276-290.
2. Anonymous. 2010. Fatal adverse drug events. I. S. M. P. Medication Safety Alert 15:1-3.
3. Blanusa M, Varnai VM, Piasek M, Kostial K. 2005. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem 12:2771-2794. (Pubitemid 41601574)
4. Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. 2007. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:401-408. (Pubitemid 47026862)
5. Cai L, Li XK, Song Y, Cherian MG. 2005. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 12:2753-2763. (Pubitemid 41601572)
6. Carven PC, Morrelli HF. 1975. Chelation therapy. West J Med 122:277-278.
7. Clarke D, Buchanan R, Gupta N, Haley B. 2012. Amelioration of acute mercury toxicity by a novel, non-toxic lipid soluble chelator N, N'bis-(2-mercaptoethyl)isophthalamide: effect on animal survival, health, mercury excretion and organ accumulation. Toxicol Environ Chem 94:616-640.
8. Dauer LT, Zanzonico P, Tuttle RM, Quinn DM, Strauss HW. 2011. The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectives. J Nucl Med 52:1423-1432.
9. Denisov ET, Afanas'ev IB. 2005. Oxidation and Antioxidants in Organic Chemistry and Biology. Boca Raton, FL, USA: CRC Press, Taylor and Francis Group.
10. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148:466-475.
11. Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. 2008. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 23:904-907.
12. Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D'Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E. 2012. Neridronate improves bone mineral density and reduces back pain in ß-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158:274-282.
13. Grier MT, Meyers DG. 1993. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504-1509. (Pubitemid 24005152)
14. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. 2010. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol 85:430-438.
15. Kontoghiorghes GJ. 2005. Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: from molecular interactions to clinical effects and applications. Curr Med Chem 12:2661-2662.
16. Kontoghiorghes GJ. 2009a. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed) 1:161-178.
17. Kontoghiorghes GJ. 2009b. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin 33:332-338.
18. Kontoghiorghes GJ. 2010. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 9:633-641.
19. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. 2005. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem 12:2663-2681. (Pubitemid 41601566)
20. Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A. 2009. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin 33:386-397.
21. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. 2012. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J 163:7-12.
22. Lewin MR. 1997. Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J 24:81-89. (Pubitemid 27273123)
23. Miller CW. 2012. The Fukushima radiological emergency and challenges identified for future public health responses. Health Phys 102:584-588.
24. Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. 2007a. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 18:329A.
25. Rajapurkar MM, Beliga R, Shah S. 2007b. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 18:57-58A.
26. Schwartz A. 2010. FDA reports. Exjade. 2474 reported reactions/deaths. http://www. fda-reports. com/exjade/reaction/death/page1. html.
27. Tefler P, Goen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. 2006. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91:1187-1192. (Pubitemid 44408428)
28. Wood JC, Ghugre N. 2008. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 32:85-96. (Pubitemid 351264532)